Top Industry Leaders in the Addison’s Disease Market
Novartis initiated a Phase 3 study in July 2023 investigating the efficacy and safety of pasireotide LAR for Addison's disease. This potential long-acting somatostatin analog therapy could offer improved convenience and compliance for patients.
Corcept Therapeutics is conducting a Phase 2b study assessing mifepristone for the treatment of autoimmune adrenal insufficiency (Addison's disease). This potential steroidogenic inhibitor could offer a novel treatment option with potentially fewer side effects.
In November 2023, Spruce Biosciences presented positive results from their Phase 2 clinical trial evaluating tildacerfont, an investigational therapy for congenital adrenal hyperplasia (CAH), which often co-occurs with Addison's disease. These results could pave the way for further development of tildacerfont for patients with both conditions.
List of Addison’s Disease Key Companies in the Market
- Pfizer Inc
- Boehringer Ingelheim International GmbH
- Shire
- Tocris Bioscience
- GlaxoSmithKline plc
- Merck KGaA
- Lupin Pharmaceuticals, Inc
- Abbott
- Amgen Limited & Amgen Ireland Limited
- Bayer AG
- Biogen
- Eli Lilly and Company
- Novartis AG
- Diurnal
- Switzer Life science Pvt. Ltd